Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing short-term operational pressure due to domestic industry policy factors and has increased strategic investments, leading to a 5.02% year-on-year decline in revenue for 2024, totaling 2.014 billion yuan [5][4] - Despite the short-term challenges, the company has made significant advancements in high-end ultrasound and endoscopy products, indicating a potential for future growth [5][6] - The company is expected to recover with projected revenue growth rates of 23%, 22%, and 22% for 2025, 2026, and 2027 respectively, alongside a significant rebound in net profit [8][9] Summary by Sections Recent Performance - In 2024, the company reported total revenue of 2.014 billion yuan, a decrease of 5.02% year-on-year, with net profit dropping by 68.67% to 142 million yuan [4][5] - The ultrasound business generated 1.183 billion yuan, down 3.26%, while the endoscopy business brought in 795 million yuan, down 6.44% [5] Product Development - The company launched high-end ultrasound machines S80 and P80, marking a breakthrough in the high-end ultrasound field [5] - The endoscopy sector has seen the release of several products, including the HD-580 series, which significantly improves image quality and clinical detail [5] - The company is actively developing AI applications for endoscopy quality control and has achieved regulatory certifications for several products [5] Market Strategy - The company is enhancing its domestic marketing efforts, focusing on high-end products and increasing its presence in large medical institutions [6] - Internationally, the company has improved its brand influence through new product launches and participation in academic conferences [6] Financial Projections - Revenue projections for 2025, 2026, and 2027 are 2.468 billion yuan, 2.998 billion yuan, and 3.654 billion yuan respectively, with corresponding net profits of 418 million yuan, 545 million yuan, and 732 million yuan [8][9] - The expected P/E ratios for the same years are 31.77, 24.36, and 18.14, indicating a favorable valuation trend [9]